Clonidine With Morphine in Patient Controlled Analgesia Pump in Vaso-Occlusive Crisis in Sickle Cell Disease Patient

Last updated: May 5, 2023
Sponsor: Centre Hospitalier Universitaire Saint Pierre
Overall Status: Active - Recruiting

Phase

4

Condition

Sickle Cell Disease

Red Blood Cell Disorders

Treatment

Clonidine

Clinical Study ID

NCT05848531
B0762023230104
  • Ages > 18
  • All Genders

Study Summary

Vaso-occlusive crisis are highly painful in Sickle-cell patients. Morphine is the treatment of choice for this pain. Various adjuncts have been studied for the treatment of vaso-occlusive crisis.

The investigators aimed to study the effect of clonidine associated with morphine in PCIA (patient controlled intravenous analgesia pumps) regimen. The investigators will compare it to the morphine alone in PCIA for the treatment of vaso-occlusive pain.

The investigators will measure the morphine consumption of all patient, the impact on the apparition of the morphine secondary effect and on inflammation biomarkers and the biopsychosocial respond.

Each patient will be hospitalized and follow by haematologist from the hospital, pain doctors and nurses.

It will be a double blind randomised, prospective study. The randomisation will be done by the pharmacy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Vaso-Occlusive Crisis In Sickle Cell disease Patients

Exclusion

Exclusion Criteria:

  • Minor
  • Patient's refusal
  • Pregnancy
  • Contr-indication Clonidine therapy

Study Design

Total Participants: 40
Treatment Group(s): 1
Primary Treatment: Clonidine
Phase: 4
Study Start date:
April 25, 2023
Estimated Completion Date:
February 28, 2024

Connect with a study center

  • CHU Saint-Pierre

    Bruxelles, 1000
    Belgium

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.